Gynecologic Oncology Group

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Interest, Gynecologic Oncology Group, Therapy, ASH, Rigosertib, Protein, Breast cancer, Patient, Mantle cell lymphoma, GOG, Research, FDA, Pharmacology, Neutropenia, SCC, Diarrhea, Ovarian cancer, Cancer, Development, Internet, Society, News, Face, Pharmaceutical industry, Birth control, Video game

NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline progress. Management plans to host a conference call and live webcast at 4:30 p.m. ET today to discuss these results.

Key Points: 
  • ET on Tuesday, November 14, 2023
    NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline progress.
  • “Onconova has made excellent progress in the third quarter of 2023.
  • Research and development expenses were $2.5 million for the third quarter of 2023, compared with $3.6 million for the second quarter of 2022.
  • General and administrative expenses were $2.7 million for the third quarter of 2023, compared with $2.1 million for the second quarter of 2022.

The Caris Precision Oncology Alliance Welcomes NRG Oncology

Retrieved on: 
Monday, August 14, 2023
Database, NRG, Partnership, Radiation Therapy Oncology Group, FACP, Radiation, Pathology, Cancer, Intelligence, MBA, Research, National Cancer Institute, POA, Patient, Machine learning, Medicine, Gynecologic Oncology Group, GOG, Recurrence, NCI, Breast cancer, Medical imaging

IRVING, Texas, Aug. 14, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) cooperative group, has joined the Caris Precision Oncology Alliance™ (POA).

Key Points: 
  • IRVING, Texas, Aug. 14, 2023 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) cooperative group, has joined the Caris Precision Oncology Alliance™ (POA).
  • NRG Oncology is a non-profit National Cancer Institute (NCI) National Clinical Trials Network (NCTN) cooperative group founded in 2012 as a collaboration of research legacy groups including the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).
  • "NRG Oncology is proud to pursue a collaboration with the Caris Precision Oncology Alliance.
  • The Caris Precision Oncology Alliance includes 88 cancer centers, academic institutions, research consortia and healthcare systems.

Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®

Retrieved on: 
Wednesday, September 28, 2022
GM, FACOG, OS, Therapy, HRP, Associate Director of National Intelligence and Chief Information Officer, Q&A, Gynecologic Oncology Group, Research, The Lancet, Trifecta, ICC, Ovarian cancer, Neoplasm, American Society of Clinical Oncology, Society, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Phase 1, Partnership, Gynecologic Oncology (journal), GameChanger, Gynaecology, Government, Patient, Immunotherapy, Clinical trial, Fred Hutchinson Cancer Research Center, University of Alabama, UAB, Epitope, VITAL, Obstetrics, Randomized controlled trial, Associate, DNA, GLOBE, University, KOL, Immune system, Cancer, RFS, Pharmaceutical industry, Vaccine, Medical imaging

DALLAS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Gradalis, a privately-held, late-stage biotechnology company developing immunotherapies for ovarian and other cancers, today announced that it will host a key opinion leader (KOL) webinar on the current treatment landscape for ovarian cancer and Vigil®, the company’s fully personalized, patient-specific cancer immunotherapy, on Monday, October 3, 2022 at 1:00 p.m. ET.

Key Points: 
  • Gradalis Chief Scientific Officer John Nemunaitis, M.D., will review results from VITAL, a Phase 2b clinical trial evaluating Vigil as maintenance therapy for ovarian cancer patients and the clinical development path forward.
  • Gradalis is preparing to initiate a Phase 3 trial designed for product registration of Vigil in patients with ovarian cancer.
  • His research interests include genetic/molecular determinants of racial healthcare disparities in gynecologic malignancies as well as understanding the molecular mechanisms of chemoresistance in ovarian cancer.
  • The company is preparing to initiate a clinical trial intended for product registration in patients with the HRP subtype ovarian cancer.

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Retrieved on: 
Tuesday, June 21, 2022
Time, Immunity, NK, RNA, FDA, Gynecologic Oncology Group, Safety, III, Tumor microenvironment, IV, Company, Recurrence, U.S. Securities and Exchange Commission, Cancer, Research, Private Securities Litigation Reform Act, EOC, Work, DSMB, Cell proliferation, Progression-free survival, DNA, Interim, GLOBE, Surface epithelial-stromal tumor, NASDAQ, Fast track (FDA), Phase, Ovarian cancer, Paclitaxel, Peritoneal cavity, Partnership, Data monitoring committee, CRS, Carboplatin, Patient, Toxic leukoencephalopathy, Neoplasm, Diagnosis, PFS, Malignancy, GOG, Woman, Immunotherapy, Risk, Pharmaceutical industry, Medical device, Vaccine

LAWRENCEVILLE, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that following a pre-planned interim safety review of 87 as treated patients (46 patients in the experimental arm and 41 patients in the control arm) randomized in the Phase I/II OVATION 2 Study with GEN-1 in advanced (Stage III/IV) ovarian cancer, the Data Safety Monitoring Board (DSMB) has unanimously recommended that the OVATION 2 Study continue treating patients with the dose of 100 mg/m2. The DSMB also determined that safety is satisfactory with an acceptable risk/benefit, and that weekly doses of GEN-1 were well tolerated during a course of treatment that is given over six months in combination with standard neoadjuvant chemotherapy. No dose-limiting toxicities were reported.

Key Points: 
  • The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with Stage III/IV ovarian cancer.
  • NACT is designed to shrink the cancer as much as possible for optimal surgical removal after three cycles of chemotherapy.
  • Following NACT, patients undergo interval debulking surgery, followed by three additional cycles of chemotherapy to treat any residual tumor.
  • The Company also announced that more than 87% of the projected 110 patients have been enrolled in the OVATION 2 Study.

Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, COVID 19, Bevacizumab, Private Securities Litigation Reform Act, Immunoglobulin G, Severe acute respiratory syndrome coronavirus 2, Failure, NASDAQ, Pharmacokinetics, GLOBE, Toxicity, Neoplasm, Nanoparticle, Time, GOG, Immunotherapy, Patient, Immunity, COVID, Partnership, Program, FDA, Cancer, Doxorubicin, DNA, Ovarian cancer, Gynecologic Oncology Group, Primate, Abdominal cavity, Vaccine, Congress, U.S. Securities and Exchange Commission, Vaccination, Research, Risk, Phase

LAWRENCEVILLE, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the Company’s two lead development programs.

Key Points: 
  • LAWRENCEVILLE, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation(NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the Companys two lead development programs.
  • We continue to make important progress in both of our lead development programs, and I am very pleased by the encouraging results to date, said Michael H. Tardugno, chairman, president and chief executive officer of Celsion.
  • This proof-of-concept data is comparing favorably to commercial vaccines in mouse models with this data recently reported at the World Vaccine Congress.
  • Celsions wholly owned subsidiary, Celsion GmbH, is managing ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is under investigator-sponsored development for several cancer indications.

Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer

Retrieved on: 
Wednesday, March 30, 2022
Risk, Recurrence, University, Safety, Population, NASDAQ, Sale, See, Death, HIV disease progression rates, Board, Overalls, Corcept Therapeutics, Doctor of Pharmacy, Survival, Ovarian cancer, Woman, Neoplasm, Patient, Associate, CORT, OS, Â, PFS, MD, Dor, GLOBE, Paralympic record progression track cycling – Women's 1 km time trial, Gynecologic Oncology Group, GOG, Arm, Lists of diseases, FDA, Disease, Pharmaceutical industry

As is typical of late-stage clinical trials, such women will not be enrolled in Corcepts upcoming Phase 3 trial.

Key Points: 
  • As is typical of late-stage clinical trials, such women will not be enrolled in Corcepts upcoming Phase 3 trial.
  • In this large, randomized study, women with recurrent, platinum-resistant ovarian cancer who were administered relacorilant at the time they received nab-paclitaxel exhibited meaningful improvements in progression free survival, duration of response and overall survival without increased side effects compared to women who received nab-paclitaxel alone.
  • No approved therapy has been shown to significantly extend survival compared to standard chemotherapy in women with platinum-resistant ovarian cancer.
  • Fourteen additional women in the intermittent arm and nine additional women in the comparator arm are expected to contribute to the final overall survival results.

AONN+ Announces Keynote Speaker for 2021 Annual Conference

Retrieved on: 
Monday, October 18, 2021
Lynx, Livestrong Foundation, Oncology, Caregiver, Gynecologic Oncology Group, Diagnosis, Journal, National Cancer Institute, JONS, Awareness, Survivor, Cancer, Felder, Physician, Pharmacist, Cervical cancer, Association, President's Cancer Panel, Friends, Health, National Cancer Institute (Egypt), Woman, Conference, Human, TLG, Patient, Global, District, Nursing, Research, Academy, Quality of life, Birth control, Medicine

CRANBURY, N.J., Oct. 18, 2021 /PRNewswire-PRWeb/ --The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to announce award-winning television producer and TV host, 15-year cervical cancer survivor, and internationally recognized advocate for cervical cancer awareness Tamika Felder as the keynote speaker for the 12th Annual Navigation & Survivorship Conference.

Key Points: 
  • CRANBURY, N.J., Oct. 18, 2021 /PRNewswire-PRWeb/ --The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to announce award-winning television producer and TV host, 15-year cervical cancer survivor, and internationally recognized advocate for cervical cancer awareness Tamika Felder as the keynote speaker for the 12th Annual Navigation & Survivorship Conference.
  • Felder will deliver the keynote address on Friday, November 19, 2021, via the AONN+ Annual Conference virtual platform.
  • The 2021 AONN+ annual conference will take place virtually on November 17-21.
  • More information about conference registration and agenda are available on the AONN+ conference webpage.

Florida Cancer Specialists & Research Institute Welcomes Dr. Jessica Stine

Retrieved on: 
Tuesday, January 12, 2021
Oncology, Texas Oncology, Medical specialties, Gynecologic Oncology Group

Fort Myers, Fla., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) welcomes Board-certified gynecologic oncologist Jessica Stine, MD .

Key Points: 
  • Fort Myers, Fla., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) welcomes Board-certified gynecologic oncologist Jessica Stine, MD .
  • Prior to joining FCS, Dr. Stine established herself as a well-respected gynecologic oncologist caring for patients in the Tampa Bay area.
  • About Florida Cancer Specialists & Research Institute, LLC: ( FLCancer.com )
    Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.

Genelux Announces Formation of Clinical Advisory Board on Gynecologic Cancers

Retrieved on: 
Thursday, June 4, 2020
Health, Gynecologic Oncology Group, Gynecologic oncology, Gynecologic oncology, Gog, Oncology, Fellowship, Medical specialties, Medicine

SAN DIEGO, June 4, 2020 /PRNewswire/ --Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, today announced that it has formed a Clinical Advisory Board (CAB) on gynecologic cancers that will guide clinical development of its lead clinical-stage candidate, Olvi-Vec (olvimulogene nanivacirepvec).

Key Points: 
  • SAN DIEGO, June 4, 2020 /PRNewswire/ --Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, today announced that it has formed a Clinical Advisory Board (CAB) on gynecologic cancers that will guide clinical development of its lead clinical-stage candidate, Olvi-Vec (olvimulogene nanivacirepvec).
  • Heis a Fellow of the American College of Surgeons and founding member of the Global Robotics Institute at AdventHealth, Orlando.
  • Dr. Coleman currently serves on the Board of Directors of Gynecologic Oncology Group and is a Director of GOG-Partners.
  • Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits.

Physicians’ Education Resource® Announces Transition of 11th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™ to Live Webcast

Retrieved on: 
Tuesday, April 21, 2020
Other Health, Research, Oncology, Consumer, Hospitals, Other Consumer, Science, Women, Biotechnology, Nursing, Other Science, Health, Gynaecological cancer, Cancer, Medical specialties, Health, Gynaecology, Oncology, Ovarian cancer, RTT, Gynecologic Oncology Group, Ovarian Cancer Research Alliance

Physicians Education Resource (PER), a leading resource for continuing medical education, announces the return of the International Symposium on Ovarian Cancer and Other Gynecologic Malignancies.

Key Points: 
  • Physicians Education Resource (PER), a leading resource for continuing medical education, announces the return of the International Symposium on Ovarian Cancer and Other Gynecologic Malignancies.
  • The conference will be held May 2 as a live CME-accredited webcast.
  • We are beyond excited to announce the return of our International Symposium on Ovarian Cancer and Other Gynecologic Malignancies conference, said Phil Talamo, president of PER.
  • The 11th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies is a one-day educational and scientific webcast that will focus on key topics in the management of ovarian cancer, as well as endometrial, uterine and cervical malignancies.